CCorn

Prospective registry of advanced stage cancer (PREFER) patients to assess prevalence of actionable biomarkers and driver mutations using the OmniSeq test and creation of a biobank from community cancer clinics in the United States to address disparities in precision medicine.

The scope of this pilot includes increasing uptake of Precision Medicine testing using the OmniSeq test for identifying actionable target mutations in clinically appropriate patients and improving the quality of care particularly in practices providing care to minority and underserved patient populations.Condition or Disease: Any Advanced Stage Solid Tumor

Hyperlink to Clinical Trials.gov page

Study Design

Study Type: Observational [Patient Registry]
Estimated Enrollment: 2500 Participants
Observational Model: Cohort
Time Perspective: Prospective
Start Date: April 19, 2021

Outcome Measures

Increase use of Precision Medicine testing to identify actionable biomarkers

Eligibility Criteria

Ages Eligible for Study: 18 years and older
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No
Sampling Method: Non-Probability Sample

Study Population

The study population will be any adults who is clinically diagnosed with late stage (III or IV) solid cancer